Recent advances in the treatment of early breast cancer have improved clinical outcomes and prolonged survival, especially in women with endocrine-responsive disease. However, cancer therapies including cytotoxic chemotherapy, ovarian suppression, and aromatase inhibitors can drastically reduce circulating estrogen, increasing bone loss and fracture risk. Because most women with early breast cancer will live for many years, it is important to protect bone health during cancer therapy. Several recent clinical trials combining adjuvant endocrine therapy with bisphosphonates have demonstrated efficacy for preventing cancer treatment-induced bone loss in pre-and postmenopausal women with early breast cancer. The largest body of evidence supporting the use of adjuvant bisphosphonates comes from studies with zoledronic acid; however, studies with risedronate, ibandronate, and denosumab (a biologic agent) have also demonstrated efficacy for preventing bone loss. Adding zoledronic acid to endocrine therapy prevents bone loss and improves bone mineral density (BMD). In addition, preclinical studies suggest that bisphosphonates have direct and indirect antitumor activity, such as inducing tumor cell apoptosis, reducing tumor cell adhesion and invasion, reducing angiogenesis, activating immune responses, and synergy with chemotherapy agents, among others. Clinical trials have demonstrated significantly improved disease-free survival in patients receiving adjuvant endocrine therapy plus zoledronic acid compared with endocrine therapy alone. Ongoing studies will further define the role of adjuvant bisphosphonates in maintaining bone health and improving clinical outcomes. The available evidence suggests that pre-and postmenopausal patients may receive clinical benefit from including bisphosphonates as part of their adjuvant treatment regimen for endocrine-responsive early breast cancer.
Introduction
Breast cancer is the most common malignancy and the leading malignancy-related cause of death among women worldwide: in 2007, the annual global incidence was estimated at more than 1.3 million, with nearly 465,000 deaths [Garcia et al. 2007 ]. Although premenopausal women often have more aggressive disease, the overall risk of developing breast cancer increases with age and is highest among postmenopausal women, who account for 75% of new cases [American Cancer Society, 2007; Anderson et al. 2002] . In developed countries, advances in early diagnosis and treatment of breast cancer have substantially improved survival rates and clinical outcomes [Clarke et al. 2005] , and patients live for many years [American Cancer Society, 2007; Quiet et al. 1995; Rosen et al. 1991; Rosen et al. 1989 ]. The standard of care for invasive breast cancer is surgical resection and radiotherapy followed by systemic therapy [National Comprehensive Cancer Network, 2009 ]. Although chemotherapy is recommended for hormone-receptor-negative breast cancer, and has been the standard for most premenopausal patients, the majority of patients (pre-and postmenopausal) have hormone-receptor-positive disease (56% ER + , 2039 years old; 71% ER + , 4049 years old; 75% ER + , 5059 years old; 81% ER + , 6069 years old; 84% ER + , 7079 years old; 85% ER + , !80 years old; 77.5% ER + overall) [Li et al. 2003 ], and these patients will receive adjuvant endocrine therapy [National Comprehensive Cancer Network, 2009] .
Cancer therapies that deplete estrogen levels can have a negative effect on bone physiology. Normal bone remodeling is a balanced process between resorption of existing bone by osteoclasts and synthesis of new bone by osteoblasts that is regulated by local and systemic factors including estrogen [Boyle et al. 2003 ]. As a result, estrogen has a profound influence on bone health. In general, postmenopausal women are at increased risk for bone loss, osteoporosis, and fractures because of reduced estrogen production associated with natural menopause [Cummings et al. 1998 ]. Healthy postmenopausal women lose approximately 1% of their bone mineral density (BMD) per year, and premenopausal women lose an average of less than 0.4% per year [Warming et al. 2002] . Therefore, any cancer therapy that depletes estrogen levels can accelerate bone loss in both groups.
Cancer therapy effects on bone
Endocrine therapies for hormone-responsive early breast cancer, such as ovarian suppression/ablation (e.g. with a luteinizing hormone-releasing hormone agonist [LHRH] , oophorectomy, radiotherapy, or cytotoxic chemotherapy) in premenopausal women and aromatase inhibition in postmenopausal women, markedly decrease circulating estrogen levels and are associated with increased bone loss [Lindsay et al. 1997] . In this setting, cancer treatment-induced bone loss (CTIBL) is used to refer to bone loss associated with a broad range of cancer treatments; however, aromatase inhibitor (AI)-associated bone loss (AIBL) specifically refers to bone loss associated with AI therapy. Current guidelines favor the use of AIs as the adjuvant endocrine therapy of choice in postmenopausal patients with endocrineresponsive disease [Winer et al. 2005] . In this setting, AIs have demonstrated significantly prolonged disease-free survival (DFS), reduced recurrence at distant sites, and a more favorable safety profile compared with tamoxifen [Winer et al. 2005] . However, in addition to reducing estrogen in peripheral tissues, AI treatment reduces circulating estrogen to substantially below the level generally observed with natural menopause [Brodie et al. 1999] . Consequently, women receiving AI therapy for breast cancer experience accelerated bone loss (i.e. AIBL) throughout the duration of therapy (À2.6% annually, compared with À1% in healthy postmenopausal women) [Eastell et al. 2006; Warming et al. 2002] , which translates into increased fracture incidence. For example, the elevated rate of bone loss in women receiving AI therapy in the ATAC trial resulted in a 5-year fracture incidence of 11%, nearly double the 6.6% 5-year fracture incidence in healthy postmenopausal women [Howell et al. 2005; Kanis et al. 2001] .
Chemotherapy for breast cancer can also influence bone health through hormonal and nonhormonal mechanisms. Chemotherapy causes ovarian dysfunction in a large percentage of premenopausal women [Lower et al. 1999; Bines et al. 1996; Bruning et al. 1990 ], which can be accompanied by a precipitous drop in BMD (>7%) during the first 12 months [Shapiro et al. 2001] . In premenopausal patients, ovarian dysfunction after chemotherapy is substantially more common in women older than 40 years of age and can exceed 90% in women over the age of 50 [Bines et al. 1996] . It is clear that bone loss associated with cancer therapy occurs rapidly, and fracture risk remains high even for osteopenic women [Siris et al. 2004] . As a result, pharmacologic intervention with bisphosphonates may be required to prevent the bone loss and consequent fractures associated with endocrine therapy for breast cancer.
Bisphosphonate mechanism of action
Bisphosphonates are bone matrix-targeting agents that induce osteoclast apoptosis and prevent bone resorption and the resultant bone loss [Rogers et al. 2000 ]. First-generation bisphosphonates (e.g. clodronate and etidronate) are small-molecule pyrophosphate analogues that bind to the bone surface via their carbonphosphate (P-C-P) backbone. When internalized by osteoclasts during bone resorption, cytotoxic levels of bisphosphonate metabolites accumulate in the osteoclasts, resulting in apoptosis [Rogers et al. 2000 ]. Newer nitrogen-containing bisphosphonates (N-BPs; e.g. pamidronate, ibandronate, risedronate, and zoledronic acid [ZOL]) accumulate in bone and are preferentially taken up by osteoclasts. In addition to direct cytotoxic effects, N-BPs inhibit the mevalonate pathway of post-translational protein modification, resulting in impaired osteoclast activation and function [Rogers et al. 2000] .
Evidence supporting use of adjuvant bisphosphonates for preventing bone loss associated with cancer therapy
Premenopausal patients
Several small clinical trials provide evidence for the efficacy of bisphosphonates in preventing CTIBL associated with chemotherapy-induced amenorrhea in premenopausal women. In one trial (n ¼ 73), patients who received oral (PO) clodronate had significantly less bone loss compared with controls, but bone loss was not entirely prevented (À5.8 versus À9.7% at 5 years; p < 0.01; Figure 1a ) . Another small study (n ¼ 53) demonstrated that risedronate significantly increased lumbar spine BMD compared with placebo during treatment (p < 0.02; Figure 1b ) [Delmas et al. 1997 ], but failed to prevent bone loss after therapy ended. In contrast, in another study of 170 premenopausal women with breast cancer receiving chemotherapy, oral risedronate (35 mg every week) did not prevent bone loss compared with placebo (À4.3 versus À5.4%, respectively; p ¼ 0.18 at 1 year) [Hines et al. 2009] . A small 1-year study showed that amenorrheic patients (n ¼ 22) who received pamidronate experienced small gains in lumbar spine BMD (+0.95% at 12 months; p < 0.05; Figure 1c ) [Fuleihan et al. 2005] .
A study of premenopausal women receiving chemotherapy (cyclophosphamide/methotrexate/ fluorouracil [CMF], anthracycline-based, and taxane-based regimens) for early stage breast cancer (n ¼ 101) examined the efficacy of adjuvant ZOL (4 mg intravenously [IV] every 3 months [q3mo]) for preventing CTIBL [Hershman et al. 2008] . Patients who received chemotherapy plus placebo had significant decreases in lumbar spine and total hip BMD at 6 and 12 months (À2.9 and À4.4%, respectively, for lumbar spine; À0.9 and À2.1%, respectively, for total hip; p < 0.05 for each compared with baseline). In contrast, patients receiving chemotherapy plus ZOL maintained BMD at both sites at 6 and 12 months (p ¼ 0.0001 for lumbar spine BMD and p ¼ 0.02 for total hip BMD, compared with placebo) [Hershman et al. 2008 ]. These results suggest that concomitant ZOL may prevent bone loss associated with chemotherapy in premenopausal patients.
The efficacy of ZOL (4 mg q3mo) for preventing bone loss in women with early stage breast cancer who developed chemotherapy-induced ovarian failure is currently being investigated. In the Cancer and Leukemia Group B (CALGB) 79809 study (n ¼ 439), premenopausal women with stage IIII breast cancer were randomized to adjuvant chemotherapy (with or without tamoxifen) and either upfront ZOL (4 mg IV q3mo, initiated with chemotherapy) or late ZOL (after 12 months of chemotherapy alone) [Shapiro et al. 2008 ]. Among the 166 patients with ovarian failure at 12 months, significant bone loss was observed in the chemotherapyplus-tamoxifen and the chemotherapy-alone groups (À4.3 and À9.5%, respectively). Overall, upfront ZOL significantly increased BMD compared with the BMD loss in the chemotherapy groups (+2.2 versus À6.6%; p < 0.0001) [Shapiro et al. 2008] . Further planned analyses from this trial will determine whether late ZOL can reverse bone loss that occurred during the first 12 months of therapy, and may help to assess the optimal timing of ZOL in this setting.
In addition to preventing CTIBL, ZOL has also been evaluated for preventing endocrine therapyassociated bone loss in the premenopausal setting. In a study of premenopausal women with early stage, hormone-responsive breast cancer (>96% of patients ER + ), adjuvant ZOL effectively prevented bone loss in patients receiving ovarian suppression plus endocrine therapy. The bone substudy of the Austrian Breast and Colorectal Cancer Study Group Trial 12 (ABCSG-12) enrolled 404 premenopausal women (mean age, 45 years) with early stage, hormone-responsive breast cancer [Gnant et al. 2008] . Patients received endocrine therapy (ovarian suppression with goserelin plus tamoxifen or anastrozole) alone or in combination with ZOL (4 mg IV every 6 months [q6mo]) for 3 years. At 3 years' median follow-up, patients receiving endocrine therapy alone had significant bone loss (À14.4% compared with baseline; p < 0.001), whereas patients receiving adjuvant ZOL with endocrine therapy had stable BMD. Overall, greater bone loss occurred in patients receiving goserelin-anastrozole than those receiving goserelin-tamoxifen (À17.3 versus À11.6%; p < 0.001) [Gnant et al. 2007] . At 5 years' median follow-up (2 years after cessation of therapy), patients who received endocrine therapy alone had recovered some BMD compared with the 3-year timepoint, although their lumbar spine BMD remained 6.3% below baseline levels (p ¼ 0.001) [Gnant et al. 2008 ]. During the same period, patients receiving endocrine therapy plus concomitant ZOL had a significant 4.0% (p ¼ 0.02) increase in lumbar spine BMD compared with baseline (+5.2% in the tamoxifen group, p ¼ 0.038; +3.1% in the anastrozole group, p ¼ 0.203; Figure 1d ) [Gnant et al. 2008] , and a similar but nonsignificant increase at the trochanter (+3.9%; p ¼ 0.07). Although patients receiving endocrine therapy alone experienced a few fractures during the trial, the long-term effects of ovarian suppression plus endocrine therapy on bone microarchitecture and fracture risk in premenopausal women are not presently known. Longer follow-up may help to define more clearly the long-term negative effects of endocrine therapy on bone and the importance of maintaining BMD during breast cancer treatment. In this setting, ZOL therapy combined with endocrine therapy for 3 years was well tolerated, and no significant adverse events attributable to ZOL were observed at this dose and frequency [Gnant et al. 2008; .
Overall, several clinical trials have documented accelerated bone loss in premenopausal patients who received either chemotherapy or endocrine therapy for breast cancer. It is evident that preserving bone health in premenopausal women receiving treatment for breast cancer is a growing medical need, and the available evidence suggests that such patients may benefit from the boneprotective effects of adjuvant bisphosphonate therapy.
Postmenopausal patients
Postmenopausal women already have severely diminished estrogen levels and may have significant bone loss prior to being diagnosed with breast cancer. Therefore, it is important to prevent further bone loss from endocrine therapy and thereby reduce fracture risk in these patients. Multiple clinical trials have suggested that bisphosphonates (clodronate, risedronate, ibandronate, ZOL) provide protection from bone loss during adjuvant endocrine therapy, although findings vary. Bisphosphonate treatment in these trials prevented or reduced bone loss in some instances (clodronate, risedronate), or improved BMD above baseline in others (ZOL, ibandronate). However, caution should be used when comparing results among these trials because of differences in trial design and patient populations.
An early study of PO clodronate in postmenopausal women receiving endocrine therapy first demonstrated the potential for bisphosphonates in preventing CTIBL ]. Patients in this study (n ¼ 61) were randomized to adjuvant endocrine therapy (tamoxifen or toremifene) or clodronate (1,600 mg/day PO) for 3 years. At a median follow-up of 3 years, patients receiving endocrine therapy alone had lost BMD compared with patients who had also received clodronate (À1.7 versus +1.0%; p ¼ 0.01) . Although patients in both groups experienced BMD loss 2 years after completing therapy (5 years' median follow-up), lumbar spine BMD was slightly better in patients who had received clodronate (À1.0 versus À3.2% for the control group; p ¼ 0.06) . Results from the 10-year follow-up of this study showed that clodronate reduced the incidence of osteoporosis in patients receiving endocrine therapy [Saarto et al. 2008 ]. However, both endocrine therapies used in this study were selective estrogen receptor modulators (tamoxifen and toremifene), which may have bone-sparing effects compared with AIs. Because AIs have a more profound effect on BMD, it is unclear whether PO clodronate can prevent AIBL based on this study.
Several studies have evaluated PO risedronate for preventing bone loss in postmenopausal patients receiving adjuvant endocrine therapy. In postmenopausal women receiving anastrozole (n ¼ 118), significant bone loss from baseline was observed at the spine and hip (À3.3 and À2.8%, respectively; p < 0.0001 for both) compared with agematched controls [Confavreux et al. 2007] . In this study, only patients with osteoporosis (T-score À2.5) received risedronate. Among patients with osteoporosis (n ¼ 15) who received anastrozole plus risedronate there was a nonsignificant increase in hip BMD (+1.8%; p ¼ 0.131) and a significant increase in lumbar spine BMD (+4.1%; p ¼ 0.008; Figure 2a ) [Confavreux et al. 2007] . A separate study in postmenopausal women receiving chemotherapy for breast cancer (n ¼ 87) examined the combination of risedronate (35 mg/week PO) with endocrine therapy for 2 years [Greenspan et al. 2008 ]. After 2 years, patients in the placebo arm had spine and hip BMD that were 1.62.5% lower than that of patients in the risedronate arm (p < 0.05) [Greenspan et al. 2008 ]. In the placebo arm, patients who had not received AI therapy had stable BMD, and those with AI therapy lost BMD at the spine and hip (À4.8 and À2.8%, respectively; p < 0.001 for both). In the risedronate arm, AI therapy caused a loss in lumbar spine BMD (À2.4%) [Greenspan et al. 2008] . Although promising, these results need confirmation in larger patient populations.
In the SABRE study, patients receiving anastrozole for breast cancer with baseline BMD Tscores <À1.0 at either hip or spine but !À2.0 at both sites received risedronate (35 mg/week PO; n ¼ 73) or placebo (n ¼ 65) [Van Poznak et al. 2007] . At 12 months, patients receiving anastrozole plus risedronate had significantly increased BMD compared with anastrozole alone (+1.71 versus À0.41% at the lumbar spine, p < 0.0001; +1.29 versus À0.09% at the hip, p ¼ 0.002). The bone substudy of the IBIS-II trial (n ¼ 613) examined the effect of risedronate on BMD in women receiving AI therapy for breast cancer [Singh et al. 2007 ]. After receiving anastrozole for 12 months, women with normal baseline BMD (n ¼ 162) who did not receive risedronate had significant BMD loss at the lumbar spine (À2.5 versus À0.97%; p ¼ 0.002) and hip (À1.34 versus À0.37%; p ¼ 0.02). In women who were osteopenic at baseline, risedronate prevented BMD loss at the hip compared with anastrozole alone (+0.67 versus À2.27%; p ¼ 0.01).
Although similar changes were observed in lumbar spine BMD, the difference between groups was not significant [Singh et al. 2007 ]. Thus, adjuvant risedronate prevents AIBL in osteopenic women [Singh et al. 2007; Van Poznak et al. 2007] ; however, the efficacy of risedronate in women with normal baseline BMD has not yet been determined.
Three parallel companion trials (Z-FAST, ZO-FAST and E-ZO-FAST) have evaluated the efficacy of ZOL (4 mg IV q6mo) for preventing AIBL in postmenopausal women with hormone-responsive, stage IIIIa breast cancer Schenk et al. 2007 ]. In these three companion studies (n ¼ 2,194), women were randomized to letrozole (2.5 mg/ day PO) and either upfront ZOL or delayed ZOL (initiated if BMD T-score fell below À2.0 or if patients experienced a nontraumatic fracture).
The first efficacy results from the Z-FAST study (n ¼ 602) demonstrated that patients in the delayed-ZOL group lost lumbar spine BMD and that those in the upfront-ZOL group gained BMD, producing a significant 4.4% mean between-group difference at 12 months (p < 0.0001; Figure 2b) [Brufsky et al. 2007] . After a median follow-up of 36 months, results from Z-FAST continue to demonstrate significant increases in absolute percentage change in lumbar spine (+6.7%; p < 0.0001) and total hip (+5.2%; p < 0.0001) BMD with upfront ZOL compared with delayed ZOL ]. Similar results were observed in the 36-month follow-up of the ZO-FAST trial (n ¼ 1,064), in which patients receiving upfront ZOL experienced significant increases in lumbar spine (+9.3%; p < 0.0001) and total hip (+5.4%; p < 0.0001) BMD compared with patients receiving delayed ZOL [Eidtmann et al. 2008] . At 12 months' median follow-up in the E-ZO-FAST trial (n ¼ 522), mean lumbar spine BMD increased 2.7% in the upfront-ZOL arm and decreased 2.7% in the delayed-ZOL arm (p < 0.0001) [Schenk et al. 2007] . Similarly, total hip BMD increased 1.7% in the upfront-ZOL arm and decreased 1.6% in the delayed-ZOL arm (p < 0.0001 for between-group difference) [Schenk et al. 2007 ]. In total, evidence from the Z-FAST, ZO-FAST, and E-ZO-FAST trials demonstrates that twice-yearly ZOL treatment prevents bone loss and consistently improves BMD in women receiving adjuvant AI therapy for early breast cancer.
The ARIBON trial is evaluating the efficacy of ibandronate (150 mg/month PO) for preventing AIBL in 131 postmenopausal women with hormone-responsive breast cancer receiving adjuvant anastrozole [Lester et al. 2008] . In this study, osteopenic women (n ¼ 50) were randomized to anastrozole plus either placebo or ibandronate. Patients receiving placebo experienced decreased BMD compared with baseline at the 12-and 24-month follow-up (À2.35 and À3.22%, respectively, at the lumbar spine; À2.27 and À3.90%, respectively, at the total hip), whereas BMD significantly increased with ibandronate (+3.11 and +2.98%, respectively, at the lumbar spine; +0.98 and +0.6%, respectively, at the total hip; p < 0.01 at all timepoints for ibandronate versus placebo) [Lester et al. 2008 ].
In addition to bisphosphonates, denosumab, a human monoclonal antibody that targets the receptor activator of nuclear factor-kB ligand (RANKL), has shown efficacy for preventing AIBL in a phase II, placebo-controlled study (n ¼ 252) ]. Postmenopausal women with hormone-receptor-positive breast cancer receiving adjuvant AI therapy also received either denosumab or placebo every 6 months. In patients receiving placebo, lumbar spine BMD declined at 12 and 24 months (À0.7 and À1.4%, respectively). However, patients receiving denosumab had significant increases in lumbar spine BMD at the same timepoints (+4.8 and +6.2%, respectively; p < 0.0001 versus placebo for both).
Taken together, data from several clinical trials demonstrate that including bisphosphonates with adjuvant AI therapy in postmenopausal patients with endocrine-responsive breast cancer can significantly improve BMD during cancer therapy. Current guidelines for preventing fractures in postmenopausal women recommend lifestyle interventions and dietary supplements (calcium and vitamin D) for all patients, along with bisphosphonate therapy for patients with osteoporosis [Johnell and Hertzman, 2006; Hillner et al. 2003 ]. In addition, World Health Organization (WHO), National Osteoporosis Foundation (NFO), and American Society of Clinical Oncology (ASCO) guidelines recommend therapy for osteopenic patients with breast cancer, depending on their individual risk factors [Johnell and Hertzman, 2006; National Osteoporosis Foundation, 2008; Hillner et al. 2003 ]. Recently, several expert panels also developed guidance for preventing CTIBL and AIBL, and for the use of bisphosphonates in patients with breast cancer. These panels provide more detailed recommendations for assessing fracture risk in individual patients, consider AI treatment an additional risk factor for fracture in women with BMD T-score <À1.5, and recommend therapeutic intervention before the onset of osteoporosis Hadji et al. 2008 ]. An expert group in the United Kingdom has recommended two separate treatment algorithms for pre-and postmenopausal women [Reid et al. 2008] . Both algorithms categorize patients into high-, medium-, and low-risk groups based on BMD T-scores, and clinical risk factors are also included as part of the fracture risk assessment in postmenopausal patients. All three published recommendations suggest evaluating clinical risk factors, such as age, AI use, family fracture history, corticosteroid or alcohol use, and smoking, with or without BMD, to determine overall fracture risk and whom to treat. Although not specifically designed for women with breast cancer, the FRAX index (www.shef.ac.uk/ FRAX) was recently developed to assess individual fracture risk based on several potential risk factors, and is being increasingly used to evaluate the need for therapeutic intervention to preserve bone health [Kanis, 2009] . Thus, physicians have a variety of resources to help guide treatment decisions for maintaining skeletal health in the postmenopausal setting for early breast cancer, and the overall consensus indicates that bone loss and fractures can be prevented by timely bisphosphonate therapy.
Potential role for bisphosphonates in preventing disease recurrence A variety of preclinical evidence suggests that N-BPs possess inherent anti-tumor activity [Winter et al. 2008a] . Bisphosphonates have demonstrated antiproliferative and proapoptotic efficacy as monotherapy in cell lines and in animal models of human breast cancer, and have been shown to act synergistically with cytotoxic agents as adjuvant therapy [Winter et al. 2008b; Mundy, 2002] . Furthermore, preclinical evidence supports the utility of bisphosphonates for inhibiting tumor-cell migration and invasion [Winter et al. 2008] . Moreover, there is evidence that ZOL inhibits angiogenesis and activates the immune system against cancer cells, thereby enhancing its overall antitumor actions [Winter et al. 2008] . Overall, these data suggest that adding bisphosphonates to endocrine therapy or chemotherapy may provide additional antitumor and antimetastatic activity [Mundy, 2002] . Because of this potential for antitumor effects, bisphosphonates are being investigated in clinical studies of adjuvant breast cancer therapy, and recent trials have elucidated their antitumor activity in premenopausal and postmenopausal women.
The ABCSG-12 trial compared tamoxifen with anastrozole and endocrine therapy alone with endocrine therapy plus ZOL (4 mg IV q6mo) in 1,803 premenopausal women with early stage endocrine-responsive breast cancer receiving ovarian suppression therapy with goserelin. The primary endpoint of ABCSG-12 was DFS for the comparison of anastrozole versus tamoxifen and ZOL versus no ZOL [Gnant et al. 2009 ]. At a median follow-up of 48 months, there was no significant difference in DFS for anastrozole versus tamoxifen (hazard ratio [HR] ¼ 1.10; p ¼ 0.59) [Gnant et al. 2009 ]. In contrast, adding ZOL to adjuvant endocrine therapy significantly improved DFS by 36% compared with adjuvant endocrine therapy alone (54 versus 83 events; HR ¼ 0.64; log-rank p ¼ 0.01; Figure 3 ) [Gnant et al. 2009 ]. Similarly, the secondary endpoint of recurrence-free survival was improved by 35% with ZOL treatment compared with endocrine therapy alone (54 versus 82 events; HR ¼ 0.65; log-rank p ¼ 0.01) and produced a trend toward improved overall survival (16 versus 26 events; HR ¼ 0.60; log-rank p ¼ 0.10) [Gnant et al. 2009 ]. ZOL treatment reduced the incidence of bone metastases and decreased recurrence at all sites compared with adjuvant therapy alone. Moreover, ZOL was not significantly associated with serious adverse events, there were no confirmed cases of osteonecrosis of the jaw, and no renal tolerability issues were noted. Overall, adding ZOL to adjuvant endocrine therapy was generally well tolerated, reduced endocrine therapy-associated bone loss, and effectively improved clinical outcomes in premenopausal women with early stage breast cancer [Gnant et al. 2009; .
The effect of ZOL on disease recurrence and DFS in postmenopausal women with breast cancer was evaluated as a secondary endpoint in the three companion trials Z-FAST, ZO-FAST, and E-ZO-FAST [Frassoldati et al. 2009; Brufsky et al. 2008 ]. The 24-month integrated analysis of Z-FAST and ZO-FAST (total n ¼ 1,667) demonstrated that upfront ZOL significantly improved DFS compared with delayed ZOL (HR ¼ 0.573; p ¼ 0.0183) [Frassoldati et al. 2009] . Similarly, the 36-month analysis of ZO-FAST (n ¼ 1,064) found that patients in the upfront-ZOL group experienced reduced disease recurrence and improved DFS compared with patients in the delayed-ZOL group (HR ¼ 0.588; p ¼ 0.0314) [Eidtmann et al. 2008 ]. These exploratory data suggest that adding ZOL to AI therapy in postmenopausal women can improve disease outcomes beyond bone health.
In addition to the potential role in adjuvant therapy for breast cancer, the efficacy of bisphosphonates has been examined in combination with neoadjuvant chemotherapy. The neoadjuvant subset analysis (n ¼ 205) from the ongoing AZURE trial (n ¼ 3,360) examined the effect of neoadjuvant chemotherapy with or without ZOL on residual invasive tumor size and pathologic complete response in patients with stage II or III breast cancer. Patients who received neoadjuvant chemotherapy plus ZOL had a significant 33% reduction in residual invasive tumor size (p ¼ 0.002) at the time of surgery and a nearly two-fold increase in pathologic complete response (p ¼ 0.03) compared with standard therapy [Winter et al. 2008 ]. Furthermore, patients who received ZOL were less likely to require a mastectomy.
In 1889, Stephen Paget proposed that the bone microenvironment influences tumor growth ('seed and soil' hypothesis) [Paget, 1889] , which may offer a partial explanation for improved DFS in ZOL-treated patients. In the Z-FAST, ZO-FAST, and E-ZO-FAST studies, and in the bone substudy of ABCSG-12, ZOL (4 mg IV q6mo) effectively prevented CTIBL and AIBL, possibly rendering the bone microenvironment a less favorable 'soil' for tumor growth. Because bone marrow is believed to be a sanctuary for tumor (stem) cells that may eventually metastasize to other distant locations, eliminating tumor cells within this niche would logically reduce disease recurrence by removing a source of metastatic cells.
Indeed, several studies have shown reduced micrometastases in the bone marrow of ZOLtreated breast cancer patients. Emerging data from four separate translational studies (n ¼ 435) indicate that, when added to standard therapies, ZOL reduces the prevalence and persistence of disseminated tumor cells (DTCs) in the bone marrow of women receiving adjuvant endocrine therapy, chemotherapy, or both [Solomayer et al. 2009; Lin et al. 2008; Rack et al. 2007] . Moreover, in the neoadjuvant chemotherapy setting, the proportion of patients with stage II/III breast cancer (n ¼ 119) who were DTC free at 3 months was larger for chemotherapy plus ZOL compared with chemotherapy alone (30 versus 47%, p ¼ 0.054) [Aft et al. 2008] . Taken together, these data suggest that adjuvant ZOL can reduce DTCs in the bone marrow and therefore may reduce or eliminate a potential source of metastatic tumor cells.
In addition, preclinical studies demonstrated direct and indirect antitumor effects of ZOL, and these additional antitumor effects are also likely to play important roles in improving DFS. For example, a single dose of ZOL decreased circulating levels of cytokines and angiogenic factors within 48 hours after infusion in patients with breast cancer [Ferretti et al. 2005] . Another study in patients with advanced cancer showed that repeated, low-dose ZOL caused a significant decrease in serum vascular endothelial growth factor (VEGF) levels after the first infusion (p ¼ 0.038) that persisted throughout subsequent infusions [Santini et al. 2007 ]. ZOL may also increase antitumor immune surveillance through activation of gd T-cells. One in vitro study demonstrated that ZOL activation of gd T-cells enhanced their cytotoxic activity against cancer cells [Muraro et al. 2007 ]. In patients with breast cancer, a single dose of ZOL induced long-term activation of gd T-cell subsets [Santini et al. 2009 ]. ZOL can also inhibit tumor cell proliferation and induce tumor cell apoptosis [Clezardin et al. 2005] , and has shown dose-dependent inhibitory effects on invasion and adhesion of cancer cells [Coxon et al. 2004; Denoyelle et al. 2003 ]. In addition, there is evidence that ZOL can act synergistically with cytotoxic chemotherapy to substantially reduce tumor growth in a mouse model of breast cancer [Ottewell et al. 2008a; . Taken together, these early clinical data as well as the preclinical studies provide rationale for the mechanisms of the anti-tumor effects of ZOL. The combined direct and indirect antitumor actions of ZOL (Figure 4) [Mundy, 2002] may explain reductions in disease recurrence in skeletal and nonskeletal sites observed in recent clinical trials.
Conclusion
The efficacy of bisphosphonates for preventing CTIBL and AIBL in pre-and postmenopausal women with breast cancer has been demonstrated in a large number of recent trials. Outstanding questions to be addressed by longterm follow-up from these trials include the consequences of increasing BMD in patients with normal BMD at baseline, and the effects of bisphosphonates on bone microarchitecture, strength, and fracture risk over time. Recent results indicate that adding bisphosphonates to conventional adjuvant therapy at doses that prevent bone loss can also significantly improve clinical outcomes in women with early stage ER + breast cancer. Early studies of adjuvant clodronate demonstrated improved outcomes, although the results of these trials were mixed, and a metaanalysis showed no benefit [Ha and Li, 2007] . The majority of evidence to date for the antitumor activity of bisphosphonates comes from the clinically relevant outcomes observed in studies of women receiving adjuvant endocrine therapy combined with ZOL for ER + breast cancer (i.e. significantly improved DFS). In this setting, ZOL may protect bone health and at the same time reduce the risk of disease recurrence. Indeed, results from ABCSG-12, Z-FAST, and ZO-FAST suggest that including adjuvant ZOL may improve the standard of care in pre-and postmenopausal women with ER + breast cancer receiving adjuvant endocrine therapy. With longterm follow-up of these trials, the potential role of adjuvant bisphosphonates may become more apparent. Unfortunately, the efficacy of bisphosphonates specifically in women with ER À breast cancer has not been explored, and the promising results of these trials can only be applied to women with clearly defined ER + breast cancer.
Although the bisphosphonate dosing regimens reviewed herein vary considerably-from daily to twice yearly-the appropriate treatment schedule should be based on the rate of bone turnover and the level of disease burden. For example, the available evidence suggests that ZOL (4 mg) administered every 6 months effectively prevents CTIBL and AIBL in premenopausal and postmenopausal patients. The same dosing schedule also reduces disease recurrence and improves DFS in patients with early breast cancer. However, 4 mg every 6 months is not sufficient to address the higher rate of bone turnover and high tumor burden associated with bonemetastatic disease. Similar comparisons of dosing regimens may also be drawn for other bisphosphonates. Although bisphosphonates have demonstrated efficacy for the prevention of CTIBL within the context of clinical trials, regulatory authorities have not approved the use of bisphosphonates for this indication and they should be considered investigational only.
Several ongoing trials will provide further insight into the potential role for adjuvant bisphosphonates (and denosumab) in breast and other cancers (e.g. AZURE, NSABP B-34, SWOG 0307, SUCCESS, NATAN, AZAC, GAIN, ICE, ZEUS, RADAR, STAMPEDE, study 2419, and ABCSG-18). These trials may offer important information concerning the best treatment regimens for each respective indication based on the level of disease burden.
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Micrometastases

Inhibits angiogenesis
Inhibits bone resorption
Synergy with anticancer drugs [Mundy, 2002] .
Stimulates immune surveillance ( T cells)
Decreases adhesion to bone
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